AstraZeneca: presents new data at ECCMID
' The company will present 19 abstracts at the event that will highlight the continuing need to protect at-risk individuals from the increased burden of common infectious diseases and the important role of long-acting antibodies and vaccines ' says the group.
Data will be presented in particular on the efficacy of Beyfortus (nirsevimab), a long-acting antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV).
Data will also be presented on sipavibart, an experimental long-acting antibody for the prevention of COVID-19 in immunocompromised people.
Iskra Reic, Executive Vice President, Vaccines and Immunotherapies, AstraZeneca, said: 'We are proud of the difference our preventive therapies are making in reducing the burden of respiratory infections, with new real-world data highlighting the efficacy of our long-acting antibody Beyfortus in preventing childhood hospitalizations due to RSV.'
"In addition, our data provide evidence that immunocompromised individuals continue to face a significant and disproportionate burden of COVID-19, underscoring the need for additional protection."
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction